Alto Neuroscience appoints former Biogen CMO Maha Radhakrishnan to board

Alto Neuroscience, Inc.

Dr. Radhakrishnan, age 54, appointed as Class I director effective March 8, 2024; term expires at 2025 Annual Meeting.
Former Group SVP and Chief Medical Officer at Biogen (Jan 2020 – Mar 2024); earlier roles at Sanofi and Bioverativ.
Board determined she is independent under NYSE and SEC rules; will serve on Nominating and Corporate Governance Committee.
Receives initial option for 30,574 shares vesting over 3 years, annual option for 15,287 shares, and cash retainers ($40k board + $5k NCGC).
Company entered standard indemnification agreement with Dr. Radhakrishnan.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Maha Radhakrishnan

Director

ANRO · Alto Neuroscience, Inc.

Effective: 2024-03-08
Filed: March 11, 2024, 7:59 PM ET

On March 8, 2024, the Board of Directors (the “Board”) of Alto Neuroscience, Inc. (the “Company”), following the recommendation of the Nominating and Corporate Governance Committee of the Board (the “NCGC”), appointed Maha Radhakrishnan, M.D., to serve as a member of the Board and as a member of the NCGC.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Maha Radhakrishnan was appointed as Director at Alto Neuroscience, Inc..

Action: appointed
Role: Director

Exact text from the filing

On March 8, 2024, the Board of Directors (the “Board”) of Alto Neuroscience, Inc. (the “Company”), following the recommendation of the Nominating and Corporate Governance Committee of the Board (the “NCGC”), appointed Maha Radhakrishnan, M.D., to serve as a member of the Board and as a member of the NCGC.

View on SEC.gov

Alto Neuroscience, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-064372

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.